ABBV Jan 2025 145.000 put
| Previous Close | 4.6400 |
| Open | 4.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 145.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 4.5500 - 4.6400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
PR NewswireAbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcome
ZacksAbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
GuruFocus.comAbbVie Inc's Dividend Analysis
AbbVie Inc (NYSE:ABBV) recently announced a dividend of $1.55 per share, payable on 2024-05-15, with the ex-dividend date set for 2024-04-12. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into AbbVie Inc's dividend performance and assess its sustainability.
